Multimedia Release

Innovative treatment for parasites affecting 1.5 billion people shows safety and superior efficacy in phase II-III trial

The novel drug, a fixed-dose combination of albendazole and ivermectin, seeks to offer a better tool against soil-transmitted helminths and help endemic countries reach the control goals set in WHO's 2021-2030 Roadmap for Neglected Tropical Diseases

Peer-Reviewed Publication

Mundo Sano España

Innovative Treatment for Parasites Affecting 1.5 billion People Shows Safety and Superior Efficacy in Phase II-III trial

video: 

Video animation explains the importance of the results of this phase II/III clinical trial in advacing a novel drug that can help achieve the control goals set by WHO's 2021-2030 Roadmap for the intestinal parasites known as soil-transmitted helminths (STH)

view more 

Credit: STOP2030.org

Journal

The Lancet Infectious Diseases

DOI

10.1016/S1473-3099(24)00669-8

Method of Research

Randomized controlled/clinical trial

Subject of Research

People

Article Title

Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial

Article Publication Date

10-Jan-2025

COI Statement

Jaime Algorta is employee of Laboratorios Liconsa. All other authors declare no competing interests

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.